Azenta Authorizes $250 Million Share Repurchase Program

Rhea-AI Summary

Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.

The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.

Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.

Positive

• $250 million repurchase authorization
• Program active from Dec 9, 2025 to Dec 31, 2028
• Execution flexibility: open market and 10b5-1 methods

Negative

• Authorization is non‑binding; no guaranteed repurchases
• Repurchases may be suspended or discontinued at any time
• Uses up to $250 million of capital through 2028

Key Figures

Share repurchase authorization $250M Maximum common stock repurchases under new program

Q4 FY2025 revenue $159M Quarter ended September 30, 2025

FY2025 revenue $594M Full year fiscal 2025

FY2025 Adjusted EBITDA $66M (11.2% margin) Full year fiscal 2025

Cash & securities $546M As of FY2025 year-end

FY2026 organic growth 3–5% Guidance for FY2026 organic revenue growth

Share price $35.60 Pre-news price from market context

52-week range $23.91–$55.64 52-week low and high from market context

Market Reality Check

$35.60 Last Close

Volume Volume 961,944 vs 20‑day average 726,889 shows elevated trading interest ahead of the buyback news. normal

Technical Price $35.60 is trading above the 200-day MA $31.42, indicating a pre-existing upward bias.

Peers on Argus

Peers show mixed moves today: some declines (e.g., STAA -6.84%, NNNN -18.85%) alongside modest gains (e.g., ATRC +1.74%, PLSE +0.96%), pointing to stock-specific rather than sector-driven dynamics for AZTA.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 21	Earnings results	Positive	+16.3%	Q4 and full-year FY2025 results with revenue growth and margin improvement.
Nov 12	Conference call notice	Neutral	-2.9%	Scheduled date and webcast details for upcoming Q4 and full-year call.
Nov 04	Strategic partnership	Positive	+1.2%	Partnership with PRECEDE Foundation to support pancreatic cancer detection study.
Oct 15	Investor day	Positive	+4.7%	Announcement of Investor Day with facility tour and executive presentations.
Aug 05	Earnings results	Positive	-17.0%	Q3 FY2025 results with flat revenue, margin gains, and reiterated full-year guidance.

Pattern Detected

Recent fundamentally positive updates, especially earnings, have often coincided with strong positive price reactions, though one earnings release saw a sharp selloff despite improved metrics.

Recent Company History

This announcement of a $250M repurchase follows several months of operational and investor-relations milestones. Azenta reported Q4 FY2025 revenue of $159M and full-year revenue of $594M on Nov 21, 2025, with improving adjusted EBITDA margin and FY2026 guidance for 3–5% organic growth. Earlier in 2025 it reiterated guidance, partnered with PRECEDE on sample management, and hosted investor-focused events. The new buyback fits into an ongoing capital allocation and engagement narrative.

Market Pulse Summary

This announcement introduces a share repurchase program authorizing up to $250M in buybacks through December 31, 2028. It follows FY2025 results showing revenue of $594M, adjusted EBITDA of $66M, and $546M in cash and securities, plus guidance for 3–5% organic growth in FY2026. Key factors to watch include the pace of actual repurchases, margin progress versus the planned ~300 bps expansion, and continued balance sheet strength.

Key Terms

share repurchase program financial

"has approved a share repurchase program under which the company may repurchase"

A share repurchase program is when a company buys back its own shares from the marketplace. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's prospects. For investors, it often suggests that the company believes its stock is undervalued or that it has extra cash to return to shareholders.

rules 10b-18 regulatory

"or by other methods compliant with Rules 10b-18 and 10b5-1 of the"

A set of U.S. Securities and Exchange Commission rules that gives companies a clear method for buying back their own shares without being accused of manipulating the market, provided they follow specific limits on timing, price, volume and the role of the broker. For investors, adherence signals that buybacks are structured and predictable, which can affect share supply, short-term price support and confidence in corporate use of cash — like rules for driving a company repurchase safely through traffic.

10b5-1 regulatory

"methods compliant with Rules 10b-18 and 10b5-1 of the Securities Exchange Act"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

AI-generated analysis. Not financial advice.

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation. Repurchases may be made from time to time through open market repurchases, privately negotiated transactions, or by other methods compliant with Rules 10b-18 and 10b5-1 of the Securities Exchange Act of 1934, subject to market and business conditions, applicable legal requirements, and other factors.

This authorization does not obligate Azenta to repurchase any specific dollar amount or number of shares, and repurchases may be commenced, suspended, modified, or discontinued at any time without prior notice. The Repurchase Program commenced on December 9, 2025, and continues until December 31, 2028, unless extended or terminated earlier by the Board.

"Our capital allocation strategy is grounded in four key levers — driving productivity and gross margin improvement, accelerating organic growth, pursuing strategic M&A with discipline, and returning capital to shareholders through share repurchases," said John Marotta, President and Chief Executive Officer. "The share repurchase authorization reflects our deliberate use of these levers to enhance long-term shareholder value while maintaining strategic flexibility to invest in growth."

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the share repurchase program and its potential benefits. Forward-looking statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could affect results include, among others, market conditions, business performance, stock price fluctuations, legal and regulatory requirements, and general economic conditions. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Maria Isabel Cuartas
Manager, Investor Relations
ir@azenta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-authorizes-250-million-share-repurchase-program-302638219.html

SOURCE Azenta

FAQ

What does Azenta's $250 million repurchase program mean for AZTA shareholders?

It authorizes up to $250 million to buy back shares, which can support EPS and return capital but is non‑binding and subject to market conditions.

When did Azenta's repurchase program for AZTA start and when does it end?

The program commenced on Dec 9, 2025 and continues until Dec 31, 2028 unless the Board extends or terminates it earlier.

How will Azenta execute share repurchases under the AZTA program?

Repurchases may occur via open market transactions, privately negotiated trades, or other methods compliant with Rules 10b-18 and 10b5-1.

Is Azenta required to repurchase the full $250 million under the AZTA authorization?

No. The authorization does not obligate Azenta to repurchase any specific dollar amount or number of shares.

Can Azenta pause or stop the AZTA buyback program?

Yes. Repurchases may be commenced, suspended, modified, or discontinued at any time based on business, market, or legal factors.